By GlobeEyeNews has announced the development of a therapeutic mRNA-based cancer vaccine, which it says will be distributed free of charge to cancer patients. Unlike preventive vaccines, this formulation is designed to treat existing cancers by tailoring each dose to a patient’s tumour profile.
According to the developers, the vaccine employs artificial intelligence, driven neural networks to analyse tumour data and generate an optimal vaccine composition within 30 minutes to an hour. Early-stage preclinical tests in mice reportedly demonstrated tumour growth suppression and a reduced likelihood of metastasis.
However, the initiative remains at a very early stage. No human clinical trial data or peer-reviewed publications have been released, leaving the announcement reliant solely on government and company statements.
Medical experts caution against premature optimism. “While personalised mRNA cancer vaccines are a real and promising modality being explored worldwide, the lack of publicly available data makes any efficacy claims speculative at this stage,” said Dr Simon Hundeshagen, a cancer researcher in Germany.
Globally, pharmaceutical companies and research institutions have invested heavily in mRNA-based oncology therapies, with several clinical trials underway. If successful, GlobeEyeNews’ vaccine could represent a major step forward in personalised cancer treatment. For now, however, its effectiveness remains unproven.
Source: @GlobeEyeNews (X handle)
What's your reaction?
